Weekly Digest - March 2025

Weekly Digest - March 2025

26 Mar 2025: GV20 Therapeutics announces collaboration agreement with Mitsubishi Tanabe Pharma Corporation to develop novel antibody-drug conjugates

  • GV20 Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic research collaboration to develop novel antibody-drug conjugates (ADCs)
  • MTPC will use GV20’s antibodies, discovered through its STEAD AI platform, to target novel tumor antigens for potential first-in-class ADC therapies
  • The collaboration will combine GV20’s antibody discovery expertise with MTPC’s linker-payload technology and therapeutics development
  • GV20 will receive an upfront payment and milestone payments, while MTPC has exclusive rights to negotiate a license for the antibodies during the collaboration

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home